Blue Jet Healthcare Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q2 FY26 earnings call: what management guided on revenue, margins and order book.

Published 6 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹11.1K Cr

The company anticipates stable to growing order book momentum with strong medium to long-term visibility fueled by global customer commitments. The company expects stable to improving revenues in the contrast media segment over the next 12-18 months, driven by commercial-scale launch of new iodinated intermediates and growth in the NCE molecule for MRI.

From Blue Jet Healthcare Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

📊 Revenue & Sales Performance

→The company anticipates stable to growing order book momentum with strong medium to long-term visibility fueled by global customer commitments.
→Capacity expansions at Vizag (103 acres) and backward integration facility at Mahad are on track, with Phase-I at Vizag targeting completion by FY '28, adding 1,000 KL capacity over 2-3 years.
→Growth in the cardiovascular drug segment (notably Bempedoic Acid) is expected to continue, with triple-digit percentage growth reported and approvals in new markets like Japan expanding opportunities.
→Contrast media shipments faced transit delays but volumes and revenues are expected to normalize and sustain at FY '23 levels over the next 12-18 months.
→Pharma intermediate and API revenues showed strong H1 growth, with new product launches and capacity enhancements poised to support scaling.
→Overall, growth drivers include multiple late-stage NCE/R&D projects, new market entries, and stable gross margins with gradually improving margin profiles due to backward integration and resilience building.

📈 Profitability & Margins

→The company expects stable to improving revenues in the contrast media segment over the next 12-18 months, driven by commercial-scale launch of new iodinated intermediates and growth in the NCE molecule for MRI.
→The Pharma Intermediates and API segment is poised for good growth, especially with expansion in chronic disease molecules and triple combination therapies.
→Backward integration at Mahad is expected to improve business continuity and margins gradually over the next few quarters.
→Capacity expansions, including a Rs. 1,000 crore Phase-I development at Vizag, will add 1,000 KL capacity by FY '28, supporting medium-term growth aspirations.
→EBITDA margins have remained healthy at 36% in Q2 FY '26, with expectations of more stable gross margins going forward due to reduced volatility in transit-related issues.
→The company is focused on disciplined execution and capacity-led growth to sustain quality earnings and margin expansion over the medium to long term.

See what Blue Jet Healthcare Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→Blue Jet Healthcare is expanding capacity with a major CAPEX plan including a new 103-acre site in Vizag.
→Phase-I of Vizag project, with an approximate CAPEX of Rs. 1,000 crores, will have 4 blocks: 2 for Contrast Media, 1 for high-intensity Sweetener, and 1 multipurpose block including peptide fragments for GLPs; expected completion by FY '28.
→Backward integration facility at Mahad with a CAPEX of about Rs. 300 crores (increased from Rs. 250 crores due to automation); commissioning expected by H2 FY '26.
→A state-of-the-art R&D center is planned in Hyderabad at a cost of Rs. 40 crores to enhance capabilities including peptides, GLP1 intermediates, and biocatalysts.
→Over the next 2-3 years, the company plans to add another 1,000 KL capacity to keep pace with client requirements.
→Total capital investment supports strategic independence, supply chain resilience, and growth in chronic disease and innovator-focused molecules.

💰 Fundraising & Capital Structure

→The company currently remains debt-free with robust internal accruals supporting its expansion plans (Page 4).
→No specific mention of new fundraising through debt or equity in the discussed transcript.
→Expansion, including the Mahad backward integration facility and Vizag site development (Phase-I CAPEX approx. Rs. 1,000 crores), appears to be funded internally through accruals.
→The focus remains on capital discipline while scaling up capacity and innovation (Page 4).
→Overall, no announced plans or indications of raising funds via new debt or equity rounds as of the quarter ended September 30, 2025.

See what Blue Jet Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

→The order book visibility for contrast media (marketed product) remains stable as per management comments.
→The order book for intermediates, specifically for the NCE molecule, is noted to be encouraging.
→Commercial scale supply for iodinated intermediates expected to commence in Q4 of the financial year.
→Management emphasized a long-term view on capacity build-up aligned with orders, indicating visibility over 5 years, though ramp-up timing may vary by 12-18 months.
→Customer off-take and schedules cause some quarter-on-quarter volatility but overall order book remains solid.
→Growth prospects for Pharma Intermediate segment, including Bempedoic Acid and other chronic disease molecules, supported by good order visibility and new approvals.
→Strong long-term contracts in place protecting capacity utilization and opportunity in key molecules like Bempedoic Acid.
→Transit and channel inventory destocking caused short-term fluctuations but normalized over the medium term, supporting steady order execution.

Key Metrics

How does Blue Jet Healthcare Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Blue Jet Healthcare Ltd

See full Pharmaceuticals & Biotechnology sector rankings

Price

₹596

Market Cap

₹11.1K Cr

P/E Ratio

47.1

Blue Jet Healthcare Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹235 Cr, net profit ₹64 Cr.

Full financials →

What BLUEJET's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Alivus Life Sciences Ltd (Q2 FY26)
Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores. Key concall takeaways from Alivus Life's Q2 FY26 earnings call — and how it ranks against sector…
Solara Active Pharma Sciences Ltd (Q2 FY26)
Current facility capacity utilization is about 70%, with capacity available to serve new customers. Key concall takeaways from Solara Active's Q2 FY26 earnings…
SUNPHARMA (Q2 FY26)
India formulation sales grew 11% in Q2, outpacing Indian Pharmaceutical Market (IPM) growth mainly driven by volume and new product launches. Key concall…
ZYDUSLIFE (Q2 FY26)
Branded formulations in India growing ahead of market at 9% YoY, driven by chronic, cardiology, gynecology, and oncology therapies. Key concall takeaways from…

Compare:vs SUNPHARMA vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Blue Jet Healthcare Ltd Q2 FY26 results?

What is Blue Jet Healthcare Ltd share price analysis?

Blue Jet Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 47.1 with a market cap of ₹11,063 Cr. Investors should review the full earnings analysis for detailed insights.

Is Blue Jet Healthcare Ltd planning capital expenditure?

Blue Jet Healthcare is expanding capacity with a major CAPEX plan including a new 103-acre site in Vizag. - Phase-I of Vizag project, with an approximate CAPEX of Rs.

Keep Blue Jet Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.